Kurs & Likviditet
Beskrivning
| Land | Norge |
|---|---|
| Lista | OB Match |
| Sektor | Hälsovård |
| Industri | Bioteknik |
2021-06-11 09:00:04
Encouraging updated preliminary survival data more than double standard of care
reported in relapsed AML patients
Bergen, Norway, 11 June 2021?- BerGenBio ASA (OSE: BGBIO), a clinical-stage
biopharmaceutical company developing novel, selective AXL kinase inhibitors for
severe unmet medical need, will present updated preliminary survival data from
the ongoing Phase II study of bemcentinib (BGBC003) in combination with low dose
cytarabine (LDAC) in elderly relapsed Acute Myeloid Leukaemia (AML) patients at
the European Haematology Association (EHA) 2021 Virtual Meeting, taking place
from 9-17 June 2021.
An update will be provided from an expansion cohort of 27 relapsed/refractory
AML patients, who were assessed to explore safety and efficacy together with
translational analysis.
The data indicate that the combination of bemcentinib, a once-daily oral AXL
-inhibitor and LDAC is efficacious and well tolerated in the elderly and unfit
relapsed AML population. Durable responses were observed in the relapsed AML
setting, with an overall response rate of 31% (5/16) and median overall survival
of 13.3 months, currently still immature and potentially subject to change.
In a subset of eleven relapsed AML patients, who received two or more cycles of
the combination, an increased clinical benefit was demonstrated